← Leaderboards
Christopher Hanyoung Lieu
University Of Colorado Denver
$1,848,400
Attributed
$1,848,400
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $548.1K · FY2015–20$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$1,848,400 · 2
By mechanism
R01$1,336,480 · 1
K23$511,920 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Paul A Bunn$21,859,370
- James V Degregori$21,700,379
- Antonio Jimeno$15,496,689
- Madeleine A Kane$15,450,424
- Mary Elaine Reyland$13,618,689
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorRefractoryInhibitor/AntagonistTissuesUniversitiesXenograft ModelColoradoDrug DevelopmentPreclinical StudyPathway InteractionsTargeted TreatmentTumor XenograftSolid NeoplasmSuccessClinical TrialsColon Cancer PatientsColorectalColorectal CancerInterestMalignant NeoplasmsMetastatic ColorectalChemotherapyTargeted AgentResponse
Grant awards (6)
Utilizing MEK Inhibition to Sensitize Microsatellite Stable Colorectal Cancer to Immune Checkpoint Therapy$548,097
R01 · FY2020 · CA · contact PI
Utilizing MEK Inhibition to Sensitize Microsatellite Stable Colorectal Cancer to Immune Checkpoint Therapy$541,043
R01 · FY2019 · CA · contact PI
Utilizing MEK Inhibition to Sensitize Microsatellite Stable Colorectal Cancer to Immune Checkpoint Therapy$247,340
R01 · FY2018 · CA · contact PI
The Development of Novel Targeted Therapy for KRAS Mutant Colorectal Cancer$170,640
K23 · FY2017 · CA · contact PI
The Development of Novel Targeted Therapy for KRAS Mutant Colorectal Cancer$170,640
K23 · FY2016 · CA · contact PI
The Development of Novel Targeted Therapy for KRAS Mutant Colorectal Cancer$170,640
K23 · FY2015 · CA · contact PI